Positive opinion for Gilead’s Hepcludex
5th May 2023 Uncategorised 0The vital recommendation ensures marketing authorisation for treating the hepatitis delta virus More: Positive opinion for Gilead’s Hepcludex Source: News
read moreThe vital recommendation ensures marketing authorisation for treating the hepatitis delta virus More: Positive opinion for Gilead’s Hepcludex Source: News
read moreSystems will support millions of patients with chronic respiratory conditions throughout Europe More: Kry showcases digital care pathways Source: News
read moreAbbVie’s Skyrizi is April’s biggest drug ad spender as some familiar names return to the top 10 badams Fri, 05/05/2023 – 04:12 More: AbbVie's Skyrizi is April's biggest drug ad spender as some familiar names return to the top 10
read moreManufacturing operations for Eli Lilly, Rentschler reprimanded by FDA esagonowsky Thu, 05/04/2023 – 14:03 More: Manufacturing operations for Eli Lilly, Rentschler reprimanded by FDA Source: fierce
read moreNovartis spruces up Sandoz—again—by bringing 6 new US generics into the fold aliu Thu, 05/04/2023 – 13:47 More: Novartis spruces up Sandoz—again—by bringing 6 new US generics into the fold Source: fierce
read moreAs Eylea sales fall again, Regeneron looks forward to approval of its longer-lasting follow-up kdunleavy Thu, 05/04/2023 – 11:00 More: As Eylea sales fall again, Regeneron looks forward to approval of its longer-lasting follow-up Source: fierce
read more© 1994 - 2024 B.M. Pharmaceuticals